Table 1 Demographic data of patients taking sodium channel blocking antiseizure medications
|  | All (n = 200) | Response (n = 109) | Not seizure-free (n = 91) | p |
|---|---|---|---|---|
Onset age (year) | 16.0 (8.0–24) | 17.5 (10.0–26.0) | 12.8 (5.5–20) | 0.001 |
Male | 100 (50.0) | 54 (49.5) | 46 (50.5) | reference |
Female | 100 (50.0) | 55 (50.5) | 45 (49.5) | 0.887 |
Seizure type | ||||
 Focal | 121 (60.5) | 62 (56.9) | 59 (64.8) | 0.265 |
 Generalized | 51 (25.5) | 24 (22.0) | 27 (29.7) |  |
 Unspecified | 28 (14.0) | 23 (21.1) | 5 (5.5) |  |
Etiology | ||||
 Structural | 38 (19.0) | 17 (15.6) | 21 (23.1) | 0.760 |
 CNS infection | 12 (6.0) | 6 (5.5) | 6 (6.6) |  |
 Genetic | 4 (2.0) | 1 (0.9) | 3 (3.3) |  |
 Autoimmune | 4 (2.0) | 1 (0.9) | 3 (3.3) |  |
 Unknown | 142 (71.0) | 84 (77.1) | 58 (63.7) |  |
Number of ASMs | ||||
 1 | 65 (32.5) | 58 (53.2) | 7 (7.7) |  |
 2 | 61 (30.5) | 37 (33.9) | 24 (26.4) |  |
 3 | 47 (23.5) | 12 (11.0) | 35 (38.5) |  |
 4 | 16 (8.0) | 2 (1.8) | 14 (15.4) |  |
 5 | 9 (4.5) | 0 (0.0) | 9 (9.9) |  |
 6 | 2 (1.0) | 0 (0.0) | 2 (2.2) |  |
Concurrent ASMs | ||||
 Carbamazepine | 49 | 26 | 23 |  |
 Clobazam | 11 | 2 | 9 |  |
 Gabapentin | 2 | 0 | 2 |  |
 Lacosamide | 3 | 0 | 3 |  |
 Lamotrigine | 70 | 35 | 35 |  |
 Levetiracetam | 80 | 26 | 54 |  |
 Oxcarbazepine | 22 | 7 | 15 |  |
 Perampanel | 11 | 0 | 11 |  |
 Phenobarbital | 19 | 1 | 12 |  |
 Phenytoin | 40 | 22 | 18 |  |
 Pregabalin | 3 | 0 | 3 |  |
 Topiramate | 41 | 13 | 28 |  |
 Valproic acid | 72 | 40 | 32 |  |
 Vigabatrin | 4 | 0 | 4 |  |
 Zonisamide | 28 | 4 | 24 |  |